• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Our people > Leadership > R&D
Jadel Kratz

Jadel Kratz

Head of Discovery and R&D Partnership, Latin America, DNDi

  • Jadel Kratz
  • @JardaKratz

Jadel Kratz, Head of Discovery and R&D Partnerships Latin America, joined DNDi in June 2016 as Project Coordinator of the Lead Optimization Latin America (LOLA) consortium.

Jadel is a pharmacist with over 15 years of experience conducting early-stage drug discovery projects across several therapeutic indications. Prior to joining DNDi, he held various positions within the academic and industrial settings, including R&D Coordinator at Cristália Produtos Químicos Farmacêuticos (Brazil), and University Assistant at University of Vienna (Austria). During this period, he developed experience as R&D project leader and fostered skills related to the development of collaborative networks and alliance management.

Jadel holds a PhD in Pharmaceutical Sciences from Universidade Federal de Santa Catarina (Brazil) and completed a visiting research fellowship at the Uppsala University (Sweden) and a postdoctoral fellowship at the Innsbruck University (Austria).

Featured news & publications

Loading...
  • Validated LC-MS/MS method for quantifying the antiparasitic nitroimidazole DNDI-0690 in preclinical target site PK/PD studies
  • Quantitative analysis of DNDI-6174 using UPLC-MS/MS: A preclinical target site pharmacokinetic study
  • Discovery and early optimization of 1H-indole-2-carboxamides with anti-Trypanosoma cruzi activity
  • Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices
  • Demystifying in vivo bioluminescence imaging of a Chagas disease mouse model for drug efficacy studies
  • Synthesis and anti-Trypanosoma cruzi activity of 3-cyanopyridine derivatives
  • AI is a viable alternative to high throughput screening: a 318-target study
  • Evento em Campinas marca apoio à ciência latino-americana contra doenças negligenciadas
  • Inovação nas universidades: a saída contra doenças negligenciadas
  • Preclinical data do not support the use of amiodarone or dronedarone as antiparasitic drugs for Chagas disease at the approved human dosing regimen

Featured events

Loading...
  • MedTrop 2025
  • BrazMedChem 2025
  • EFMC-ASMC 2025
  • PAGE 2025
  • 5th Iberoamerican Symposium on Organic Chemistry (SIBEAQO-V)

Our global footprint

Loading...
Female healthcare worker taking care of a little girl

DNDi Eastern Africa

DNDi Japan

Female patient discussing with doctor

DNDi Latin America

Female doctor with a patient in a hospital

DNDi North America

Community worker talking with people in a rural village

DNDi South Asia

Malaysian doctor talking with a man in a hospital

DNDi South-East Asia

Two people speaking in an office

DNDi Switzerland

Doctors talking with patient in hospital

DNDi West and Central Africa

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license